IsoPSA Performance Characteristics Are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results from the IsoPSA Validation Study

    February 2023 in “ Urology ”
    Jason Scovell, Mark Stovsky, Alan W. Partin, Yair Lotan, Jack Baniel, Martin Dineen, Jason Hafron, Kannan Manickam, Marc Pliskin, Matthew Wagner, Aimee Kestranek, Eric A. Klein
    Studysummary This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms. Our plain-language summary of this paper — not a Tressless recommendation.
    The study involving 888 men aged 50 and above found that the IsoPSA test's performance in detecting prostate cancer is unaffected by the use of 5-alpha reductase inhibitors (5-ARIs) and alpha-blockers, which are common medications for benign prostatic hyperplasia. IsoPSA maintained consistent sensitivity across all groups, with increased specificity in patients using alpha-blockers. Although the small sample size for the 5-ARI cohort (n=40) may limit the detection of minor changes, the findings suggest that IsoPSA is a reliable diagnostic tool for prostate cancer detection in patients taking these medications.
    Discuss this study in the Community →